First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive <br />early breast cancer (EBC) Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
30
Embed
First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive <br />early breast cancer (EBC)
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
TARGETING HER2 IN BREAST CANCER: EVOLVING CONCEPTS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 3
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 4
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 5
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 6
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 7
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Primary Endpoint
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
SECONDARY EndpointS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
STAtiStical considerations
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Current Analysis Plan
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 12
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
CONSORT TABLE
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 14
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Distribution of the Stratification Factors by Treatment Arm
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Distribution of patient characteristics by Treatment Arm
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 17
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
DISEASE-FREE SURVIVAL (DFS) ANALYSIS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
DFS BY Hormone Receptor Status
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
DFS by Chemotherapy Timing
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
OVERALL SURVIVAL (OS) ANALYSIS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
DFS NON-INFERIORITY ANALYSIS<br />Note: Null hypothesis hazard ratio is 1.11
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 23
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
PROPORTION OF PATIENTS RECEIVING ≥ 85% OF THE PLANNED DOSE OF ANTI-HER2 DRUGS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 25
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
MAIN DIFFERENCES IN AEs BY TREATMENT ARM
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
CARDIAC SAFETY
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
CONCLUSIONS (I)
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
CONCLUSIONS (II)
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Acknowledgements
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting